Elaine Hochberg joined Forest Laboratories Inc. in 1997 as Vice President of Marketing, and she has helped the drug company achieve significant growth and reach multiple milestones since then. In 1998, Hochberg headed marketing efforts for Celexa® (citalopram HBr), a major success that transformed and expanded Forest Laboratories, leading to an upgrade of its listing from small to mid-size on the New York Stock Exchange in 1999.
In 2000, Elaine Hochberg and her colleagues celebrated the company’s topping $1 billion in net sales for the first time. Hochberg’s efforts contributed to the company’s winning DIANA awards from the National Wholesale Druggists’ Association in 2002 for the anti-hypertensive drug Benicar® (olmesartan medoxomil) (co-promoted with Daiichi Sankyo) and the antidepressant drug Lexapro® (escitalopram oxalate). Through the years, Hochberg assumed increased marketing responsibilities as Forest Laboratories developed and acquired new drugs or companies, such as ceftaroline and Cerexa Inc., and formed multiple new partnerships.
In 2010, Elaine Hochberg earned a promotion to Chief Commercial Officer and Executive Vice President. Since then, Forest has launched several new drugs, including Teflaro® (ceftaroline fosamil), which fights bacterial infections; Viibryd™ (vilazodone HCl), which treats people with major depressive disorder; and Daliresp™ (roflumilast), for chronic obstructive pulmonary disease (COPD). Hochberg assumed new marketing roles with these launches, and with the acquisition of drug company Clinical Data.
Today, Elaine Hochberg oversees all marketing and sales functions, market research, new product planning, and managed care pursuits. A pharmaceutical veteran, Hochberg possesses 25 years of experience in the industry. In her 14 years with Forest Laboratories, she has helped launch and market a significant number of new drugs. She lives in New York City.